A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.
- Conditions
- Refractory wtKRAS metastatic colorectal cancerMedDRA version: 14.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2012-000167-25-FR
- Lead Sponsor
- ICANCER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 75
1.Metastatic colorectal cancer expressing the wtKRAS status
2.No previous EGFR targeted therapy.
3.Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease
4.Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC)
5.Life expectancy of at least 3 months.
6.Patient with ECOG = 1
7.Patients aged = 18.
8.Patient with measurable lesions according to RECIST criteria (version 1.1) with spiral CT scan and defined as = 10 mm in longest diameter and 2X the slice thickness for extra nodal lesions and/or > 15 mm in short axis diameter for nodal lesions
9.Patient able to receive adequate oral nutrition of = 1500 calories per day and free of significant nausea and vomiting
10.Patient with adequate organ function:
•Absolute neutrophil count (ANC) = 1.5 x 109/L
•Haemoglobin = 9 g/dL
•Platelets (PTL) = 100 x 109/L
•AST/ALT = 2.5 x ULN (= 5 x ULN in case of liver metastases)
•GammaGT < 3 x ULN (< 5 x ULN in case of liver involvement)
•Bilirubin = 1.5 x ULN
•Creatinine clearance = 50 mL/min (Cockcroft and Gault formula)
11.Adequate contraception if applicable.
12.Ability to take oral medication in the opinion of the investigator.
13.Patient able and willing to comply with study procedures as per protocol
14.Patient able to understand and willing to sign and date the written voluntary informed consent form at screening visit prior to any protocol-specific procedures
15.Patient affiliated to a social security regimen
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1.Previous EGFR targeted therapy.
2.Mutant KRAS status
3.Prior severe reaction to a monoclonal antibody
4.Clinically relevant cardiovascular abnormalities, as judged by the investigator, such as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA classification > III, unstable angina, myocardial infarction within six months prior to randomisation, or poorly controlled arrhythmia
5.Cardiac left ventricular dysfunction with resting ejection fraction of less than institutional lower limit of normal (if no lower limit of normal is defined in the institution, the lower limit is 50%)
6.Symptomatic brain metastases requiring treatment
7.Major surgery within 28 days or minor surgery within 14 days of the start of the study treatment
8.Radiotherapy less than two weeks prior to the start of the study treatment
9.Systemic chemotherapy, hormonal therapy, immunotherapy = 28 days before study treatment
10.No major comorbidity that may preclude the delivery of treatment or active infection (HIV or chronic hepatitis B or C) or uncontrolled diabetes.
11.Concomitant occurrence of another cancer, or history of cancer within the past five years except in situ carcinoma of the cervix treated or basal cell carcinoma or squamous cell carcinoma.
12.Known pre-existing interstitial lung disease
13.Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn’s disease, malabsorption, or CTCAE grade >2 diarrhea of any etiology
14.Pregnant woman or lactating woman.
15.Persons deprived of liberty or under guardianship.
16.Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Non Progression rate at 6 months;<br> Secondary Objective: •Objective response rate based on RECIST v1.1, <br> •Safety and tolerability of afatinib and cetuximab combo,<br> •Progression Free survival (PFS)<br> •Overall survival <br> ;Primary end point(s): The primary endpoint non progression rate will be presented by the percentage of patients without progression at 6 months with the 95% confidence interval.;Timepoint(s) of evaluation of this end point: 6 months
- Secondary Outcome Measures
Name Time Method